Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

AVXL

Anavex Life Sciences Corp

2.70

Jul 09 • 04:00PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: ACIU NGEN VYGR DTIL EDIT ARTV PALI PRLD RZLT TARA

| Held by: VTI IWM VXF IWN IBB VTWO SCHA IWC VHT SMLF

Scroll to Statements

Index	RUT
Market Cap	250.21M
Enterprise Value	118.46M
Income	-39.95M
Sales	0.00M
Book/sh	1.37
Cash/sh	1.42
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	34
IPO	Aug 02, 2006

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.98
P/C	1.90
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	20.87
Current Ratio	20.87
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.46
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	4.47% -3.79%
Sales past 3/5Y	- -
EPS Y/Y TTM	15.81%
Sales Y/Y TTM	-
EPS Q/Q	55.32%
Sales Q/Q	-
Earnings	May 07
EPS/Sales Surpr.	51.34% -

Insider Own	3.12%
Insider Trans	0.00%
Inst Own	43.42%
Inst Trans	1.56%
ROA	-31.08%
ROE	-33.63%
ROIC	-31.55%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	3.96%
SMA50	-4.36%
SMA200	-41.06%
Trades

Shs Outstand	92.67M
Shs Float	89.78M
Short Float	19.52%
Short Ratio	14.65
Short Interest	17.53M
52W High	13.99 -80.70%
52W Low	2.41 12.03%
Volatility	5.51% 5.97%
ATR (14)	0.16
RSI (14)	50.67
Beta	1.16
Rel Volume	0.75
Avg Volume	1.20M
Volume	895,752

Perf Week	4.65%
Perf Month	3.05%
Perf Quarter	-11.18%
Perf Half Y	-32.67%
Perf YTD	-24.16%
Perf Year	-74.91%
Perf 3Y	-66.91%
Perf 5Y	-89.23%
Perf 10Y	-64.38%
Recom	1.00
Target Price	20.00
Prev Close	2.70
Price	2.70
Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
May-04-26	Initiated	Rodman & Renshaw	Buy	$20
Dec-06-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$16 → $11
Jun-23-22	Initiated	Berenberg	Buy	$40
Sep-23-21	Initiated	BTIG Research	Buy	$35
Dec-16-20	Reiterated	H.C. Wainwright	Buy	$14 → $17
Sep-28-20	Initiated	Ladenburg Thalmann	Buy	$12
Feb-27-20	Initiated	Cantor Fitzgerald	Overweight
Jun-18-19	Initiated	Janney	Buy
May-16-18	Resumed	Maxim Group	Buy	$5 → $7
Mar-08-18	Initiated	ROTH Capital	Buy	$6
Feb-13-18	Reiterated	Maxim Group	Buy	$14 → $5
Sep-29-17	Resumed	Noble Financial	Buy	$15
Feb-07-17	Initiated	Noble Financial	Buy	$16
Mar-29-16	Initiated	FBR Capital	Outperform	$10

Show Previous Ratings

May-22-26 08:00AM	Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification (GlobeNewswire)
May-06-26 10:52AM	CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus (InvestorsHub)
07:00AM	Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer (GlobeNewswire)
May-04-26 09:43AM	AMD downgraded, Airbnb upgraded: Wall Street's top analyst calls (The Fly)
Apr-14-26 07:30AM	Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer's Disease (GlobeNewswire)
07:30AM	Loading…
Apr-07-26 07:30AM	Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-30-26 07:30AM	Anavex Life Sciences Provides Comprehensive Regulatory Update (GlobeNewswire)
Mar-25-26 07:30AM	Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease (GlobeNewswire) -34.61%
Mar-23-26 07:30AM	Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer's Disease (GlobeNewswire) +9.36%
Mar-20-26 07:30AM	New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer's Disease (GlobeNewswire)
Mar-17-26 07:30AM	Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson's Disease at AD/PD 2026 Conference (GlobeNewswire)
Mar-05-26 08:27AM	Anavex Life Sciences Touts Oral Alzheimers Drug Blarcamesine Data, Cash Runway at Healthcare Conference (MarketBeat)
Mar-04-26 01:32PM	What's Going On With Anavex Life Sciences Stock On Wednesday? (Benzinga) +6.61%
Mar-03-26 07:30AM	Anavex Life Sciences to Present at the Citizens Life Sciences Conference (GlobeNewswire)
Mar-02-26 09:40AM	Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year? (Zacks)
07:30AM	Loading…
Feb-25-26 07:30AM	Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference (GlobeNewswire)
Feb-23-26 07:30AM	Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors (GlobeNewswire)
Feb-12-26 12:00PM	Anavex Life Sciences (AVXL) Upgraded to Buy: Here's What You Should Know (Zacks)
09:40AM	Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-09-26 10:06AM	Anavex Life Sciences Q1 Earnings Call Highlights (MarketBeat) +6.10%
07:35AM	Anavex Life Sciences: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update (GlobeNewswire)
Feb-03-26 07:30AM	Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 (GlobeNewswire)
Jan-15-26 04:06AM	Anavex Life Sciences Highlights Oral Alzheimers Drug Blarcamesine, Precision Strategy at JPM Conference (MarketBeat)
Jan-13-26 07:30AM	Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer's Disease (GlobeNewswire) +8.16%
Jan-08-26 07:30AM	Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology (GlobeNewswire)
Jan-06-26 07:30AM	Anavex Life Sciences Receives FDA Feedback on Alzheimer's Disease Program (GlobeNewswire)
Dec-18-25 07:30AM	Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion (GlobeNewswire)
Dec-12-25 04:05PM	Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease (GlobeNewswire)
Dec-02-25 09:35AM	Down 50.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Anavex Life Sciences (AVXL) (Zacks)
07:30AM	Loading…
Nov-26-25 07:30AM	Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire) +11.56%
Nov-25-25 04:00PM	Anavex Life Sciences Corp (AVXL) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com) +12.34%
07:47AM	Anavex Life Sciences: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update (GlobeNewswire)
Nov-19-25 07:30AM	Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference (GlobeNewswire)
Nov-18-25 07:30AM	Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025 (GlobeNewswire)
Nov-14-25 07:30AM	Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease (GlobeNewswire) -35.94%
Oct-29-25 07:30AM	Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group (GlobeNewswire)
Oct-10-25 07:30AM	Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference 'Connecting Science and Communities: The Future of Dementia Care' (GlobeNewswire)
Oct-02-25 07:35AM	Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX3-71 Program (GlobeNewswire)
07:30AM	Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX3-71 for the Treatment of Schizophrenia (GlobeNewswire)
Sep-30-25 08:30AM	Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease Trial (GlobeNewswire)
Sep-24-25 08:38PM	H.C. Wainwright Reiterates Its 'Buy' Rating on Anavex Life Sciences Corp. (AVXL) with a $42 Price Target (Insider Monkey)
Sep-09-25 07:30AM	Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial (GlobeNewswire) +9.73%
Sep-02-25 07:30AM	Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025 (GlobeNewswire)
Aug-26-25 07:30AM	Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine (GlobeNewswire)
Aug-20-25 07:31AM	Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication Shows (Benzinga)
07:30AM	Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease (GlobeNewswire)
Aug-13-25 01:00PM	Anavex Life Sciences Corp (AVXL) Q3 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Aug-12-25 01:59PM	Anavex Life Sciences: Fiscal Q3 Earnings Snapshot (Associated Press Finance) -5.02%
07:30AM	Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-25 07:30AM	Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025 (GlobeNewswire)
Aug-01-25 08:29AM	Anavexs blarcasemine nets win in Phase IIb/III Alzheimers extension study (Clinical Trials Arena)
Jul-31-25 07:31AM	Anavex Life Sciences: Early Blarcamesine Treatment Cuts Alzheimer's Progression by 20 Months (Benzinga)
07:30AM	Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease (GlobeNewswire)
Jul-10-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Anavex Life Sciences (AVXL) is a Great Choice (Zacks)
Jul-04-25 09:40AM	Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year? (Zacks)
May-14-25 05:01PM	Anavex Life Sciences Corp (AVXL) Q2 2025 Earnings Call Highlights: Promising Alzheimer's Data ... (GuruFocus.com)
07:30AM	Anavex Life Sciences to Participate at Upcoming Healthcare Conferences (GlobeNewswire)
May-13-25 07:37AM	Anavex Life Sciences: Fiscal Q2 Earnings Snapshot (Associated Press Finance) -5.03%
07:30AM	Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update (GlobeNewswire)
May-09-25 08:25AM	Is Anavex Life Sciences Corp. (AVXL) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-06-25 07:30AM	Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 (GlobeNewswire) -7.63%
May-01-25 07:30AM	Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX3-71 for the Treatment of Schizophrenia (GlobeNewswire)
Apr-30-25 07:30AM	Anavex Life Sciences to Participate in The Citizens Life Sciences Conference (GlobeNewswire)
Apr-23-25 07:30AM	Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board (GlobeNewswire)
Apr-21-25 04:41PM	Anavex Life Sciences Corp (AVXL) Q1 2025 Earnings Call Highlights: Promising Alzheimer's Data ... (GuruFocus.com) +5.14%
07:30AM	Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East (GlobeNewswire)
Apr-13-25 05:13AM	Anavex: A Small Bit Of Progress Against Alzheimer's Disease (Seeking Alpha)
Apr-11-25 03:00PM	Undercovered Dozen: VICI Properties, General Dynamics, LandBridge, Anavex + (Seeking Alpha)
Apr-07-25 06:31PM	Anavex: Understanding Their Alzheimer's Open-Label Extension Data Skeptically (Seeking Alpha) -8.76%
12:49PM	AD/PD 2025: Long-term data shows Anavexs Blarcamesine benefits in early Alzheimers (Clinical Trials Arena)
12:10PM	Anavex Life Sciences Reports Prolonged Benefit Data Of Blarcamesine In Early Alzheimer's Over 3 Years (Benzinga)
Apr-05-25 11:30AM	Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease (GlobeNewswire)
Mar-31-25 07:30AM	Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Feb-24-25 07:30AM	Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-12-25 07:39AM	Anavex Life Sciences: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update (GlobeNewswire)
Feb-05-25 07:30AM	Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025 (GlobeNewswire)
Jan-31-25 08:10AM	Jim Cramer on Anavex Life Sciences Corp. (AVXL): Its A Good Spec (Insider Monkey)
Jan-27-25 07:30AM	Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX 2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio (GlobeNewswire) -6.39%
Jan-15-25 09:00PM	Lightning Round: Sell Viking Therapeutics, says Jim Cramer (CNBC TV) +8.21% -10.41%
07:30AM	Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease (GlobeNewswire)
Jan-13-25 07:30AM	New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients (GlobeNewswire) -6.06%
Jan-06-25 07:30AM	Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.15%
Dec-31-24 09:40AM	Are Medical Stocks Lagging Anavex Life Sciences (AVXL) This Year? (Zacks)
Dec-30-24 12:00PM	All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Buy (Zacks) -8.84%
Dec-27-24 06:15AM	Anavex price target raised to $42 from $40 at H.C. Wainwright (TipRanks)
Dec-26-24 01:00AM	Anavex Life Sciences Faces Manufacturing Challenges Impacting Product Launch and Financial Stability (TipRanks) +15.55%
Dec-24-24 02:00AM	Anavex Life Sciences Corp (AVXL) Q4 2024 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Dec-23-24 11:17PM	Q4 2024 Anavex Life Sciences Corp Earnings Call (Thomson Reuters StreetEvents) +29.55%
07:43AM	Anavex Life Sciences: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer's Disease (GlobeNewswire)
Dec-22-24 05:00AM	What To Expect in the Markets This Week (Investopedia)
Dec-16-24 07:30AM	Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024 (GlobeNewswire) +8.51%
Dec-09-24 07:30AM	Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference (GlobeNewswire)
Dec-02-24 07:30AM	Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024 (GlobeNewswire)
Nov-26-24 07:30AM	Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer's Disease to EMA (GlobeNewswire)
Nov-25-24 07:30AM	Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal (GlobeNewswire)

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

CGAMs. Sandra Boenisch CPA

Interim Chief Executive OfficerDr. Terrie Kellmeyer Ph.D.

VP of CorporateClint Tomlinson

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MISSLING CHRISTOPHER U	President and CEO	Sep 11 '25	Option Exercise	5.04	187,500	945,000	1,655,213	Sep 12 07:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVXL

Anavex Life Sciences Corp

Upgrade your Finviz experience